<?xml version="1.0" encoding="UTF-8"?>
<doc:document xmlns:doc="http://www.elsevier.com/xml/document/schema"
              xmlns:dp="http://www.elsevier.com/xml/common/doc-properties/schema"
              xmlns:cps="http://www.elsevier.com/xml/common/consyn-properties/schema"
              xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
              xmlns:dct="http://purl.org/dc/terms/"
              xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/"
              xmlns:oa="http://vtw.elsevier.com/data/ns/properties/OpenAccess-1/"
              xmlns:bam="http://vtw.elsevier.com/data/voc/ns/bam-vtw-1/"
              xmlns:cp="http://vtw.elsevier.com/data/ns/properties/Copyright-1/"
              xmlns:cja="http://www.elsevier.com/xml/cja/schema"
              xmlns:ja="http://www.elsevier.com/xml/ja/schema"
              xmlns:bk="http://www.elsevier.com/xml/bk/schema"
              xmlns:ce="http://www.elsevier.com/xml/common/schema"
              xmlns:mml="http://www.w3.org/1998/Math/MathML"
              xmlns:cals="http://www.elsevier.com/xml/common/cals/schema"
              xmlns:tb="http://www.elsevier.com/xml/common/table/schema"
              xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/schema"
              xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/schema"
              xmlns:xlink="http://www.w3.org/1999/xlink">
   <rdf:RDF>
      <rdf:Description rdf:about="http://dx.doi.org/10.1016/j.phyplu.2022.100228">
         <dct:format>application/xml</dct:format>
         <dct:title>Enhanced plasma persistence of ceftriaxone following single intramuscular injection with prior oral dosing of a mammary protective commercial herbal drug as complementary therapy</dct:title>
         <dct:creator>Tapas Kumar Sar</dct:creator>
         <dct:creator>Rinku Buragohain</dct:creator>
         <dct:creator>Rabindra Nath Hansda</dct:creator>
         <dct:creator>Tapan Kumar Mandal</dct:creator>
         <dct:subject>
            <rdf:Bag>
               <rdf:li>Fibrosin®</rdf:li>
               <rdf:li>Complementary therapy</rdf:li>
               <rdf:li>Ceftriaxone</rdf:li>
               <rdf:li>Disposition kinetics</rdf:li>
               <rdf:li>Intramuscular injection</rdf:li>
            </rdf:Bag>
         </dct:subject>
         <dct:description>Phytomedicine Plus 2 (2022). doi:10.1016/j.phyplu.2022.100228</dct:description>
         <prism:aggregationType>journal</prism:aggregationType>
         <prism:publicationName>Phytomedicine Plus</prism:publicationName>
         <prism:copyright>© 2022 The Author(s). Published by Elsevier B.V.</prism:copyright>
         <dct:publisher>Elsevier B.V.</dct:publisher>
         <prism:issn>2667-0313</prism:issn>
         <prism:volume>2</prism:volume>
         <prism:number>2</prism:number>
         <prism:coverDisplayDate>May 2022</prism:coverDisplayDate>
         <prism:doi>10.1016/j.phyplu.2022.100228</prism:doi>
         <prism:url>http://dx.doi.org/10.1016/j.phyplu.2022.100228</prism:url>
         <dct:identifier>doi:10.1016/j.phyplu.2022.100228</dct:identifier>
         <bam:articleNumber>100228</bam:articleNumber>
         <oa:openAccessInformation>
            <oa:openAccessStatus xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://vtw.elsevier.com/data/voc/oa/OpenAccessStatus#Full</oa:openAccessStatus>
            <oa:openAccessEffective xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">2022-01-26T06:41:40Z</oa:openAccessEffective>
            <oa:sponsor xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
               <oa:sponsorType>http://vtw.elsevier.com/data/voc/oa/SponsorType#Author</oa:sponsorType>
            </oa:sponsor>
            <oa:userLicense xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://creativecommons.org/licenses/by-nc-nd/4.0/</oa:userLicense>
         </oa:openAccessInformation>
         <cp:licenseLine xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">This is an open access article under the CC BY-NC-ND license.</cp:licenseLine>
      </rdf:Description>
   </rdf:RDF>
   <dp:document-properties>
      <dp:aggregation-type>Journals</dp:aggregation-type>
      <dp:version-number>S250.1</dp:version-number>
   </dp:document-properties>
   <ja:article docsubtype="fla" version="5.6" xml:lang="en">
      <ja:item-info>
         <ja:jid>PHYPLU</ja:jid>
         <ja:aid>100228</ja:aid>
         <ce:article-number>100228</ce:article-number>
         <ce:pii>S2667-0313(22)00014-8</ce:pii>
         <ce:doi>10.1016/j.phyplu.2022.100228</ce:doi>
         <ce:copyright type="other" year="2022">The Author(s)</ce:copyright>
      </ja:item-info>
      <ja:head>
         <ce:title id="tte0002">Enhanced plasma persistence of ceftriaxone following single intramuscular injection with prior oral dosing of a mammary protective commercial herbal drug as complementary therapy</ce:title>
         <ce:author-group id="aut0001">
            <ce:author id="au0001"
                       author-id="S2667031322000148-4c3e1fb7eb9369dc1a9fd6a6c19a4931">
               <ce:given-name>Tapas Kumar</ce:given-name>
               <ce:surname>Sar</ce:surname>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/conceptualization">Conceptualization</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/methodology">Methodology</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/investigation">Investigation</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/writing-original-draft">Writing – original draft</ce:contributor-role>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="cor0001">
                  <ce:sup loc="post">⁎</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="fn1">
                  <ce:sup loc="post">1</ce:sup>
               </ce:cross-ref>
               <ce:e-address id="ead0001"
                             type="email"
                             xlink:href="mailto:tapas.sar@rediffmail.com">tapas.sar@rediffmail.com</ce:e-address>
            </ce:author>
            <ce:author id="au0002"
                       author-id="S2667031322000148-8a06bb7b113da5d098f43ce39e28e608">
               <ce:given-name>Rinku</ce:given-name>
               <ce:surname>Buragohain</ce:surname>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/validation">Validation</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/writing-review-editing">Writing – review &amp; editing</ce:contributor-role>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="fn2">
                  <ce:sup loc="post">2</ce:sup>
               </ce:cross-ref>
               <ce:e-address id="ead0002"
                             type="email"
                             xlink:href="mailto:rinkuburagohain90@gmail.com">rinkuburagohain90@gmail.com</ce:e-address>
            </ce:author>
            <ce:author id="au0003"
                       author-id="S2667031322000148-e30a662126d8b6da3ff1369209782968">
               <ce:given-name>Rabindra Nath</ce:given-name>
               <ce:surname>Hansda</ce:surname>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/resources">Resources</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/visualization">Visualization</ce:contributor-role>
               <ce:cross-ref refid="aff0002">
                  <ce:sup loc="post">b</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="fn3">
                  <ce:sup loc="post">3</ce:sup>
               </ce:cross-ref>
               <ce:e-address id="ead0003" type="email" xlink:href="mailto:drrnhansda@gmail.com">drrnhansda@gmail.com</ce:e-address>
            </ce:author>
            <ce:author id="au0004"
                       author-id="S2667031322000148-c06c98b4042d1a9b05bc6f22b440cc41">
               <ce:given-name>Tapan Kumar</ce:given-name>
               <ce:surname>Mandal</ce:surname>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/supervision">Supervision</ce:contributor-role>
               <ce:contributor-role role="http://credit.niso.org/contributor-roles/writing-review-editing">Writing – review &amp; editing</ce:contributor-role>
               <ce:cross-ref refid="aff0001">
                  <ce:sup loc="post">a</ce:sup>
               </ce:cross-ref>
               <ce:cross-ref refid="fn4">
                  <ce:sup loc="post">4</ce:sup>
               </ce:cross-ref>
               <ce:e-address id="ead0004" type="email" xlink:href="mailto:drtkm48@gmail.com">drtkm48@gmail.com</ce:e-address>
            </ce:author>
            <ce:affiliation id="aff0001"
                            affiliation-id="S2667031322000148-44323f98acd4853711a97d989b3e1899">
               <ce:label>a</ce:label>
               <ce:textfn id="cetextfn0001">Department of Veterinary Pharmacology and Toxicology, West Bengal University of Animal and Fishery Sciences, 37K. B. Sarani, Kolkata 700037, West Bengal, India</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Department of Veterinary Pharmacology and Toxicology</sa:organization>
                  <sa:organization>West Bengal University of Animal and Fishery Sciences</sa:organization>
                  <sa:address-line>37K. B. Sarani</sa:address-line>
                  <sa:city>Kolkata</sa:city>
                  <sa:state>West Bengal</sa:state>
                  <sa:postal-code>700037</sa:postal-code>
                  <sa:country>India</sa:country>
               </sa:affiliation>
               <ce:source-text id="staff0001">aDepartment of Veterinary Pharmacology and Toxicology, West Bengal University of Animal and Fishery Sciences, 37K. B. Sarani, Kolkata 700037, West Bengal, India</ce:source-text>
            </ce:affiliation>
            <ce:affiliation id="aff0002"
                            affiliation-id="S2667031322000148-7cc4e5b243c2b61ead2792c7e61a8470">
               <ce:label>b</ce:label>
               <ce:textfn id="cetextfn0002">Department of Veterinary Pathology, West Bengal University of Animal and Fishery Sciences, 37K. B. Sarani, Kolkata 700037, West Bengal, India</ce:textfn>
               <sa:affiliation>
                  <sa:organization>Department of Veterinary Pathology</sa:organization>
                  <sa:organization>West Bengal University of Animal and Fishery Sciences</sa:organization>
                  <sa:address-line>37K. B. Sarani</sa:address-line>
                  <sa:city>Kolkata</sa:city>
                  <sa:state>West Bengal</sa:state>
                  <sa:postal-code>700037</sa:postal-code>
                  <sa:country>India</sa:country>
               </sa:affiliation>
               <ce:source-text id="staff0002">bDepartment of Veterinary Pathology, West Bengal University of Animal and Fishery Sciences, 37K. B. Sarani, Kolkata 700037, West Bengal, India</ce:source-text>
            </ce:affiliation>
            <ce:correspondence id="cor0001">
               <ce:label>⁎</ce:label>
               <ce:text id="cetext0001">Corresponding author at: Department of Veterinary Pharmacology and Toxicology, West Bengal University of Animal and Fishery Sciences, 37K. B. Sarani, Kolkata-700037, West Bengal, India.</ce:text>
               <sa:affiliation>
                  <sa:organization>Department of Veterinary Pharmacology and Toxicology</sa:organization>
                  <sa:organization>West Bengal University of Animal and Fishery Sciences</sa:organization>
                  <sa:address-line>37K. B. Sarani</sa:address-line>
                  <sa:city>Kolkata</sa:city>
                  <sa:state>West Bengal</sa:state>
                  <sa:postal-code>-700037</sa:postal-code>
                  <sa:country>India</sa:country>
               </sa:affiliation>
            </ce:correspondence>
            <ce:footnote id="fn1">
               <ce:label>1</ce:label>
               <ce:note-para id="notep0001" view="all">Tapas Kumar Sar, Department of Veterinary Pharmacology and Toxicology, West Bengal University of Animal and Fishery Sciences, 37 K. B. Sarani, Kolkata-700037, West Bengal, India</ce:note-para>
            </ce:footnote>
            <ce:footnote id="fn2">
               <ce:label>2</ce:label>
               <ce:note-para id="notep0002" view="all">Rinku Buragohain, Department of Veterinary Pharmacology and Toxicology, West Bengal University of Animal and Fishery Sciences, 37 K. B. Sarani, Kolkata-700037, West Bengal, India</ce:note-para>
            </ce:footnote>
            <ce:footnote id="fn3">
               <ce:label>3</ce:label>
               <ce:note-para id="notep0003" view="all">Rabindra Nath Hansda, Department of Veterinary Pathology, West Bengal University of Animal and Fishery Sciences, 37 K. B. Sarani, Kolkata-700037, West Bengal, India, E-mail:</ce:note-para>
            </ce:footnote>
            <ce:footnote id="fn4">
               <ce:label>4</ce:label>
               <ce:note-para id="notep0004" view="all">Tapan Kumar Mandal, Department of Veterinary Pharmacology and Toxicology, West Bengal University of Animal and Fishery Sciences, 37 K. B. Sarani, Kolkata-700037, West Bengal, India</ce:note-para>
            </ce:footnote>
         </ce:author-group>
         <ce:date-received day="1" month="12" year="2021"/>
         <ce:date-revised day="12" month="1" year="2022"/>
         <ce:date-accepted day="25" month="1" year="2022"/>
         <ce:abstract id="abs0001" class="author-highlights" view="all">
            <ce:section-title id="cesectitle0001">Highlights</ce:section-title>
            <ce:abstract-sec id="abss0001" view="all">
               <ce:simple-para id="spara013" view="all">
                  <ce:list id="celist0001">
                     <ce:list-item id="celistitem0001">
                        <ce:label>•</ce:label>
                        <ce:para id="para0005" view="all">Fibrosin®, a commercial herbal drug is used for a long time as supportive therapy in mastitis.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0002">
                        <ce:label>•</ce:label>
                        <ce:para id="para0006" view="all">Fibrosin® was given orally 1 h prior to intramuscular ceftriaxone to study disposition kinetics.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0003">
                        <ce:label>•</ce:label>
                        <ce:para id="para0007" view="all">Ceftriaxone showed a reabsorption half-life (t½Ka′) of 0.18±0.003 h in presence of Fibrosin®.</ce:para>
                     </ce:list-item>
                     <ce:list-item id="celistitem0004">
                        <ce:label>•</ce:label>
                        <ce:para id="para0008" view="all">The reabsorption rate constant of ceftriaxone (3.86±0.10 h<ce:sup loc="post">−1</ce:sup>) suggested rapid intestinal reabsorption.</ce:para>
                     </ce:list-item>
                  </ce:list>
               </ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:abstract id="abs0002" view="all" class="author">
            <ce:section-title id="cesectitle0002">Abstract</ce:section-title>
            <ce:abstract-sec id="abss0003" role="background" view="all">
               <ce:section-title id="cesectitle0003">Background</ce:section-title>
               <ce:simple-para id="spara014" view="all">The herbal drug (Fibrosin®) is often used as supportive therapy with intramuscular ceftriaxone injection for treatment of mastitis in field condition.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0004" role="materials-methods" view="all">
               <ce:section-title id="cesectitle0004">Method</ce:section-title>
               <ce:simple-para id="spara015" view="all">A single oral dose of Fibrosin® (1.9 g) was given 1 h prior to single intramuscular injection of ceftriaxone at 50 mg kg<ce:sup loc="post">−1</ce:sup> in 3 apparently healthy male and 3 female goats. Plasma and urine samples were collected at predetermined time intervals and ceftriaxone/ceftizoxime was analyzed by HPLC. Ceftriaxone persisted for 3 h in plasma of Fibrosin® treated healthy goats.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0005" role="results" view="all">
               <ce:section-title id="cesectitle0005">Results</ce:section-title>
               <ce:simple-para id="spara016" view="all">Ceftriaxone showed a distinct reabsorption phase in its dispositional profile. Mean t<ce:inf loc="post">½</ce:inf> K (distribution half-life) following absorption phase and t<ce:inf loc="post">½</ce:inf> K′ (elimination half-life) following re-absorption phase were 0.091±0.01 and 0.43±0.03 h respectively with a reabsorption half-life (t<ce:inf loc="post">½</ce:inf>Ka′) of 0.18±0.003 h. Ceftriaxone at a lower concentration (67.91±9.42 μg mL<ce:sup loc="post">−1</ce:sup>) was recovered at 24 h post dosing from urine. The reabsorption rate constant was 3.86±0.10 h<ce:sup loc="post">−1</ce:sup> that suggested rapid intestinal reabsorption.</ce:simple-para>
            </ce:abstract-sec>
            <ce:abstract-sec id="abss0006" role="conclusion" view="all">
               <ce:section-title id="cesectitle0006">Conclusion</ce:section-title>
               <ce:simple-para id="spara017" view="all">Rapid intestinal absorption of ceftriaxone indicated shorter persistence in the intestine and it also exhibited enhanced plasma persistence which may help to preserve beneficial intestinal bacteria as well as prevention of antimicrobial resistance development in the intestine for which the herbal drug may be used as a supportive therapy with intramuscular injection of ceftriaxone.</ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:abstract id="abs0003" class="graphical" view="all">
            <ce:section-title id="cesectitle0007">Graphical abstract</ce:section-title>
            <ce:abstract-sec id="abss0007" view="all">
               <ce:simple-para id="spara018" view="all"> [Display omitted] </ce:simple-para>
            </ce:abstract-sec>
         </ce:abstract>
         <ce:keywords id="keys0001" view="all" class="keyword">
            <ce:section-title id="cesectitle0008">Keywords</ce:section-title>
            <ce:keyword id="key0001">
               <ce:text id="cetext0002">Fibrosin®</ce:text>
            </ce:keyword>
            <ce:keyword id="key0002">
               <ce:text id="cetext0003">Complementary therapy</ce:text>
            </ce:keyword>
            <ce:keyword id="key0003">
               <ce:text id="cetext0004">Ceftriaxone</ce:text>
            </ce:keyword>
            <ce:keyword id="key0004">
               <ce:text id="cetext0005">Disposition kinetics</ce:text>
            </ce:keyword>
            <ce:keyword id="key0005">
               <ce:text id="cetext0006">Intramuscular injection</ce:text>
            </ce:keyword>
         </ce:keywords>
      </ja:head>
   </ja:article>
</doc:document>
